Company Participants
Ryan Asay – Senior Vice President of Corporate Affairs
Mark Goldsmith – CEO, President & Chairman
Anthony Mancini – Chief Global Commercialization Officer
Alan Bart Sandler – Chief Development Officer
Jack Anders – Chief Financial Officer
Conference Call Participants
Yue-Wen Zhu – LifeSci Capital, LLC, Research Division
Tyler Van Buren – TD Cowen, Research Division
Michael Schmidt – Guggenheim Securities, LLC, Research Division
Andrea Tan – Goldman Sachs Group, Inc., Research Division
Cory Kasimov – Evercore ISI Institutional Equities, Research Division
Hyunji Sun – Morgan Stanley, Research Division
Lut Ming Cheng – JPMorgan Chase & Co, Research Division
Faisal Khurshid – Jefferies LLC, Research Division
Michael Yee – UBS Investment Bank, Research Division
Asthika Goonewardene – Leerink Partners LLC, Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Gregory Renza – Truist Securities, Inc., Research Division
Laura Prendergast – Stifel, Nicolaus & Company, Incorporated, Research Division
Alec Stranahan – BofA Securities, Research Division
Sean McCutcheon – Raymond James & Associates, Inc., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your first speaker today, Ryan Asay, Senior Vice President, Corporate Affairs. Please go ahead.
Ryan Asay
Senior Vice President of Corporate Affairs
Thank you, and welcome, everyone, to the Third Quarter 2026 Earnings Call. Joining me on today’s call are Dr. Mark Goldsmith, Revolution Medicines’ Chairman and Chief Executive Officer; Anthony Mancini, our Chief Global Commercialization Officer; Dr. Alan Sandler, our Chief Development Officer; and Jack Anders, our Chief Financial Officer. Dr. Wei Lin, our Chief Medical Officer, will join us for the Q&A portion of today’s call.
I’d like to inform you that
Credit: Source link
